Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

Philip J Mease1 Swedish Medical Center and University of Washington, Seattle, WA, USACorrespondence[email protected]

Daniel J Clauw2 Chronic Pain and Fatigue Research Center, University of Michigan Health System, Ann Arbor, MI, USA

Joel M Trugman3 Forest Research Institute, Jersey City, NJ, USA

Robert H Palmer3 Forest Research Institute, Jersey City, NJ, USA

Yong Wang3 Forest Research Institute, Jersey City, NJ, USA

Pages 679-687 | Published online: 21 Nov 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

WolfeFRossKAndersonJRussellIJHebertLThe prevalence and characteristics of fibromyalgia in the general populationArthritis Rheum199538119287818567
PubMed Web of Science ®Google Scholar
VincentALahrBDWolfeFPrevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology ProjectArthritis Care Res (Hoboken)201365578679223203795
PubMed Web of Science ®Google Scholar
GendreauRMThornMDGendreauJFEfficacy of milnacipran in patients with fibromyalgiaJ Rheumatol200532101975198516206355
PubMed Web of Science ®Google Scholar
MeasePJClauwDJGendreauRMThe efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trialJ Rheumatol200936239840919132781
PubMed Web of Science ®Google Scholar
ClauwDJMeasePPalmerRHGendreauRMWangYMilnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trialClin Ther200830111988200419108787
PubMed Web of Science ®Google Scholar
ArnoldLMGendreauRMPalmerRHGendreauJFWangYEfficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trialArthritis Rheum20106292745275620496365
PubMed Web of Science ®Google Scholar
TrugmanJMPalmerRHMaYMilnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation studyCurr Med Res Opin201430458959724188161
PubMed Web of Science ®Google Scholar
GoldenbergDLClauwDJPalmerRHDurability of therapeutic response to milnacipran for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension studyPain Med201011218019420002596
PubMed Web of Science ®Google Scholar
FerreraRPalmerRWangYGendreauRImprovements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from 2 double-blind, dose-controlled extension studies [abstract]J Pain2009104 Suppl 1S60
PubMed Web of Science ®Google Scholar
ArnoldLMPalmerRHMaYA 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgiaClin J Pain201329121021102823446068
PubMed Web of Science ®Google Scholar
ClauwDJMeasePJPalmerRHTrugmanJMWangYContinuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trialArthritis Res Ther2013154R8823953493
PubMed Web of Science ®Google Scholar
CroffordLJMeasePJSimpsonSLFibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalinPain2008136341943118400400
PubMed Web of Science ®Google Scholar
FarrarJTYoungJPJrLaMoreauxLWerthJLPooleRMClinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain200194214915811690728
PubMed Web of Science ®Google Scholar
MeasePJClauwDJChristensenRToward development of a fibromyalgia responder index and disease activity score: OMERACT module updateJ Rheumatol20113871487149521724721
PubMed Web of Science ®Google Scholar
ArnoldLMWilliamsDAHudsonJIDevelopment of responder definitions for fibromyalgia clinical trialsArthritis Rheum201264388589421953205
PubMed Web of Science ®Google Scholar
GilronIWajsbrotDTherrienFLemayJPregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trialClin J Pain201127318519321178603
PubMed Web of Science ®Google Scholar
TothCMawaniSBradySAn enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic painPain2012153102073208222921260
PubMed Web of Science ®Google Scholar
RaskinPHuffmanCTothCPregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trialClin J Pain201430537939023887339
PubMed Web of Science ®Google Scholar
Savella (milnacipran HCl) [prescribing information]St Louis, MOForest Pharmaceuticals, Inc2013
Google Scholar
BennettRMFriendRJonesKDWardRHanBKRossRLThe Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties [Erratum, Arthritis Res Ther 2009;11:415]Arthritis Res Ther2009114R12019664287
PubMed Web of Science ®Google Scholar
WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care19923064734831593914
PubMed Web of Science ®Google Scholar
BeckATSteerRABrownGKManual for the Beck Depression Inventory-IISan Antonio, TXPsychological Corporation1996
Google Scholar
BennettRMKaminMKarimRRosenthalNTramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled studyAm J Med2003114753754512753877
PubMed Web of Science ®Google Scholar
BurckhardtCSClarkSRBennettRMThe fibromyalgia impact questionnaire: development and validationJ Rheumatol19911857287331865419
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date